Topic archive
MedTech Current publications and recall entries tagged Consumables, Reagents & Sterilization.
A no-growth result could give sterile-processing staff false reassurance that a steam cycle was effective. Affected stock must be identified and destroyed, while replacement depends on remaining shelf life. The five records belong together because they cover the same product family, failure, firm, and corrective instructions.
FDA has classified the recall of Draeger VentStar Resus Neo disposable breathing circuits as Class I after cracks were found in the hose, creating a risk of leakage or disconnection that may restrict ventilation or delay therapy in infants.
FDA codified Class II special controls for room-temperature vascular autograft flushing and storage solutions. Six control categories govern the device type, while the original DuraGraft indication’s four-hour duration is product-specific. Developers should distinguish those two sources of requirements.
The same affected sponge component appears in five types of procedure kit. Hospitals therefore need to locate finished kits across specialties and remove the component as directed, while distributors pass the notice to downstream customers.
Facilities need to distinguish kits covered by the contamination update from kits affected only by the packaging-seal concern. The required response differs: some kits must be discarded, while others can be managed through quarantine and component removal.
Canada's September 2026 Domestic Substances List orders add the P flag to 204 polymer identifiers previously assessed as reduced regulatory requirement polymers. The final order covers fewer entries than the 220 proposed in February; suppliers and device manufacturers should confirm that the polymer form supplied still meets the RRR criteria.
NMPA has opened comment on revised GMP inspection guides for sterile and implantable medical devices. The drafts combine the revised general GMP with the relevant special appendices and classify findings as critical, major, or general; comments are due October 8, 2026.
FDA has classified the recall of specified AVID Medical convenience kits containing recalled Huons sodium chloride flush ampules as Class I because of product quality and sterility-assurance concerns affecting the saline components.
FDA has classified the recall of specified Medtronic Bravo CF capsule delivery devices as Class I after a deployment-control problem was linked to failures of the capsule to attach to the esophagus or detach from the delivery device as intended.
Medical Action Industries is correcting specified epidural kits containing sodium chloride flush ampules subject to a sterility-related recall. FDA classified the issue as a Class I Recall, with matching CDRH records Z-3106-2026 and Z-3107-2026.
Under new Clause 2.2 of Australia's medical device regulations, non-invasive devices containing only saline for flushing or maintaining device patency are reclassified as Class IIa, with a five-year transition for existing products.
A supplier packaging defect can propagate through many downstream procedure-kit configurations, creating substantial traceability and relabeling work for hospitals and distributors. The event also illustrates an important quantity-handling edge case: an identical event total repeated across multiple FDA records should not be summed as though each were a separate quantity.
A component-level endotoxin issue can propagate across many finished surgical-kit configurations and create substantial inventory and labeling work for healthcare organizations. The event is a useful supply-chain example because the field action focuses on identifying affected kits, controlling them in inventory, and removing the recalled component rather than discarding every complete kit.
Protein indicators are used to assess cleaning processes, so false-negative or false-positive results can undermine confidence in reprocessing verification and create unnecessary follow-up work. The event is particularly relevant to quality teams because an expired manufacturing input translated directly into performance uncertainty in a process-monitoring product.
FDA has classified the correction of AVID Medical convenience kits containing Medline Namic Star Off Handle Manifolds as Class I following reports of particulate within the fluid path, which may lead to vessel blockage, tissue ischemia, or death.
The event shows how one component-level nonconformance can propagate into many finished surgical-kit configurations and product classifications. For hospitals and manufacturers, the response depends on tracing affected kits, quarantining inventory, applying warning over-labels, removing the affected component before kit use, and notifying downstream customers when products were redistributed.
The underlying failure is comparatively simple, but the large quantity and broad distribution create substantial inventory and replacement work. The defect requires coordinated field action and downstream notification.
FDA has classified the recall of certain Medline convenience kits containing B. Braun bupivacaine hydrochloride components as Class I. Medline Industries, LP is correcting affected kits because they include Huons Bupivacaine Hydrochloride in Dextrose Injection, USP that was recalled for quality issues.
This event shows how one supplier-component problem can propagate across many finished procedural kits and generate multiple FDA records. For hospitals and supply-chain teams, the operational burden extends beyond a single SKU because affected components must be identified inside kits, clinicians notified, warning labels applied, and downstream customers addressed.